Tickernomics

10y

Historical Returns*:

SPY

27.80%

-13.89%

BRTX

SPY

32.66%

-62.65%

BRTX

SPY

108.59%

-95.16%

BRTX

SPY

302.52%

-100.00%

BRTX

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

12.59

-0.50

0.01

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-0.92

33.39

1.26

-56.75

0.00

0.05

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-979.02

92.19

-1854.40

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

189.2032

-639.65

-85.79

50.24

Other Earnings and Cash Flow Stats:

BioRestorative Therapies Inc. ( BRTX ) Net Income TTM ($MM) is -13.65

BioRestorative Therapies Inc. ( BRTX ) Operating Income TTM ($MM) is -12.09

BioRestorative Therapies Inc. ( BRTX ) Owners' Earnings Annual ($MM) is -4.98

BioRestorative Therapies Inc. ( BRTX ) Current Price to Owners' Earnings ratio is -1.65

BioRestorative Therapies Inc. ( BRTX ) EBITDA TTM ($MM) is -11.90

BioRestorative Therapies Inc. ( BRTX ) EBITDA Margin is -1854.40%

Capital Allocation:

BioRestorative Therapies Inc. ( BRTX ) has paid 0.00 dividends per share and bought back -3.550656 million shares in the past 12 months

BioRestorative Therapies Inc. ( BRTX ) has reduced its debt by 0.198724 million USD in the last 12 months

Capital Structure:

BioRestorative Therapies Inc. ( BRTX ) Interest-bearing Debt ($MM) as of last quarter is 0

BioRestorative Therapies Inc. ( BRTX ) Annual Working Capital Investments ($MM) are 0

BioRestorative Therapies Inc. ( BRTX ) Book Value ($MM) as of last quarter is 9

BioRestorative Therapies Inc. ( BRTX ) Debt/Capital as of last quarter is 0%

Other Balance Sheet Stats:

BioRestorative Therapies Inc. ( BRTX ) has 1 million in cash on hand as of last quarter

BioRestorative Therapies Inc. ( BRTX ) has 4 million of liabilities due within 12 months, and long term debt 0 as of last quarter

BioRestorative Therapies Inc. ( BRTX ) has 8 common shares outstanding as of last quarter

BioRestorative Therapies Inc. ( BRTX ) has 0 million USD of preferred stock value

Academic Scores:

BioRestorative Therapies Inc. ( BRTX ) Altman Z-Score is -14.90 as of last quarter

BioRestorative Therapies Inc. ( BRTX ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

BioRestorative Therapies Inc. ( BRTX ) largest shareholder is Geode Capital Management, LLC owning 55706 shares at 0.09 ($MM) value

Broadrick Dale(an insider) Sold 1112 shares of BioRestorative Therapies Inc. ( BRTX ) for the amount of $1756.96 on 2024-10-28

26.32% of BioRestorative Therapies Inc. ( BRTX ) is held by insiders, and 13.48% is held by institutions

BioRestorative Therapies Inc. ( BRTX ) went public on 2007-07-27

About BioRestorative Therapies Inc. ( BRTX ) :

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.